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Abstract
Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplastic proliferations showing different morphological
features, immunophenotype, molecular background, clinical presentation, and outcome. They can virtually originate in every
organ of the human body and their classification is not uniform among different sites. Indeed, as they have historically been
classified according to the organ in which they primarily arise, the different nomenclature that has resulted have created some
confusion among pathologists and clinicians. Although a uniform terminology to classify neuroendocrine neoplasms arising in
different systems has recently been proposed byWHO/IARC, some issues remain unsolved or need to be clarified. In this review,
we discuss the lights and shadows of the currentWHO classifications used to define and characterize NENs of the pituitary gland,
lung, breast and those of the head and neck region, and digestive and urogenital systems.
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1 Introduction
Neuroendocrine neoplasms (NENs) are a heterogeneous
group of epithelial neoplastic proliferations ranging from in-
dolent well differentiated neuroendocrine tumors (NETs) to
very aggressive poorly differentiated neuroendocrine carcino-
mas (NECs). They can arise virtually in any organ of the body
and, although they show similar morphological and
immunophenotypical features, they present some peculiar
site-specific characteristics. The second decade of twenty-
first century assisted to a terrific expansion of molecular tech-
nologies that has allowed an increasing insight into the path-
ogenetic mechanisms of NENs, as well as a greater under-
standing of their clinico-pathological relationships, and, last
but not the least, the recognition of new prognostic
(DAXX/ATRX, microsatellite instability, CD117 expression)
and theranostic markers (somatostatin receptor subtype 2, de-
regulation in druggable pathways such as PI3K/AKT/mTOR
and Notch signaling) [1]. In this context, several “hot topics”
in the field of NENs classification have emerged.
Synthetically, the most debated arguments have been: i) the
conceptual separation between NETs and NECs, with the
identification of distinct molecular pathogenetic pathways;
ii) the existence of highly proliferating NETs, as well as their
relationship and differential diagnosis with NECs; iii) the need
to re-define the concept of mixed neuroendocrine/
nonneuroendocrine neoplasms; iv) the growing exigence,
from both the pathologists’ and the oncologists’ point of view,
of a common framework for the nomenclature and classifica-
tion of neoplasms arising in extra-GEP organs but showing
overlapping morphological features with GEP NENs. These
issues are better discussed, for each organ or system, in the
following paragraphs. Here we present a general outline for
each of the first four points, leaving the last one a specific
discussion, later in the text.
Morphology represents the first cornerstone for the differ-
ential diagnosis between NET and NEC [2] and the combina-
tion of morphological features and Ki67 proliferative index
improves the ability in this distinction, which has important
clinical implications. Indeed, NETs and NECs should be con-
sidered as distinct clinico-pathological entities [2]. Molecular
analysis has largely confirmed this assumption, showing that
these two families of neoplasms recognize different pathoge-
netic pathways. In digestive NENs, the carcinogenesis of
NECs seems to be strongly related to that of non-
neuroendocrine carcinomas of the primary site in which they
arise, with frequent inactivation of TP53 and RB1 [3–6]. In
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contrast, NETs of the GEP system exhibit unique molecular
signatures, including, among other features, the inactivation of
MEN1, VHL, TSC1/2 genes, and the hyperactivation of the
PI3K/mTOR pathway [6, 7]. In the lung, a similar situation
has been demonstrated, but progression from NETs to NECs
has been suggested in a subset of cases, with distinct clinico-
pathological features [8, 9].
The existence of morphologically well differentiated
NETs with a high proliferation index was not included
either in the WHO classification of digestive NETs pub-
lished in 2010 [10] or in the last WHO classification of
lung tumors [11]. In fact, such tumors were classified as
NECs based on the mitotic count and/or Ki67 prolifer-
ation index, according to the classification schemes.
However, starting from clinical observations [12], it
soon became evident that NENs with high proliferation
index were morphologically, clinically and biologically
heterogeneous, both in digestive and in thoracic sites
[13–15] and the concept of NET G3 was integrated in
the classification of GEP organs, leaving the definition
of NEC to NENs with poorly differentiated morphology
[16, 17].
Mixed neoplasms with neuroendocrine and non-
neuroendocrine components, although rare, have been a
matter of speculation under both diagnostic and thera-
peutic points of view. Indeed, their morphological het-
erogeneity underlies an intrinsic difficulty in making a
correct diagnosis on small biopsy samples, as well as in
not adequately sampled surgical specimens [18]. On the
other hand, their protean biological nature must be tak-
en into account when choosing the proper treatment. In
order to better convey the diversity of this group of
neoplasms that can be composed of different combina-
tions of NENs (NET or NEC) and non-NENs (adeno-
carcinoma, acinar cell carcinoma, squamous cell carci-
noma, and others) we proposed the term Mixed
neuroendocrine/non-neuroendocrine neoplasm (MiNEN)
[19]. The term MiNEN has been accepted in the
WHO classification of GEP NENs [16, 17].
The existence of NENs in extra-thoracic and extra-
digestive organs is a well-known, albeit rare, event. Head
and neck and genitourinary tract are the commonest sites,
but any epithelial organ may virtually be affected by a NEN.
The diagnostic and therapeutic challenges of these NENs are
related to their rarity, as well as to the heterogeneous classifi-
cation schemes, which are not uniform in the various organs.
To address this issue, and with the aim to settle down the bases
of a robust and clinically significant nomenclature of NENs, a
panel of expert pathologists, under the aegis of WHO and
IARC, proposed, in 2018, a common classification frame for
NENs [20]. This represents a milestone in the history of
NENs, as it underlies the concept of a category of neoplasms
that, with important site- and grade-related variations, retains
substantial identity under morphological, biological and clin-
ical points of view.
2 Pituitary gland
Although the pituitary gland is small, it contains at least six
neuroendocrine cells types secreting different hormones and
bioactive peptides and this reflects the rather large number of
different pituitary tumor types that can be found in the adeno-
hypophysis. The pathological classification of anterior pitui-
tary tumors has traditionally been bases on morphology, im-
munohistochemistry, and electron microscopy with the aim to
correlate morphology and immunophenotype with function
and clinical presentation [21]. With the advent of molecular
techniques a large amount of new information has been ob-
tained and the use of transcription factors involved in the
lineage determination of different cell types has been pro-
posed to classify anterior pituitary tumors [22]. This approach
was the basis for the last WHO classification published in
2017 [16] that included two main tumor types: pituitary ade-
noma and pituitary carcinoma. Although this approach has the
advantage to better characterize different pituitary tumor types
based on cell lineage, it is not able to predict patients’ out-
come. Indeed, this classification does not allow identifying
with certitude those cases that will behave in an indolent man-
ner and distinguishing them from those that will locally recur
and need additional treatment, with a great impact on quality
of life. In addition, this approach does not identify tumors that
will give metastatic dissemination during follow-up, therefore
deferring the diagnosis of pituitary carcinoma a posteriori,
only when the presence of meningeal dissemination or meta-
static spread will become clinically and/or radiologically evi-
dent (Fig. 1). Moreover, in the general attempt to conceptually
unify NENs arising in the different anatomical sites, the need
was felt to include also anterior pituitary tumors in the NENs
family, to which they belong for morphological and functional
reasons. Taken together, these considerations prompted a mul-
tidisciplinary group of experts in pituitary pathology to pro-
pose the new terminology “pituitary neuroendocrine tumor
(PitNET)” instead of “pituitary adenoma” (Table 1) [23].
Thus, all anterior pituitary tumors are considered as lesions
showing a potential clinical impact that can be additionally
evaluated and better defined in terms of prognosis using a
multiparametric approach including the Ki67 proliferative in-
dex and radiology appearance (Table 2) [24, 25]. Although
this new approach appears appropriate and clinically useful
since it reflects the real biology of these tumors, it is still
matter of debate [26–28]. It is worth noting that the actual
efficacy of this terminology has been supported by the
WHO/IARC, which has recently proposed a common classi-
fication framework for neuroendocrine tumors to be used for
all body sites [20].
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3 Head and neck
NENs of the head and neck are a group of heterogeneous
epithelial neoplastic proliferations arising in virtually all the
different organs of this region, including the nasal cavity,
paranasal sinuses, nasopharynx, larynx, salivary glands, and
middle ear. Their morphological and clinical features mainly
depend on the degree of differentiation and on the site of
origin and for these reasons they will be discussed separately
in the following paragraphs.
In this region, the larynx is the commonest site of occurrence
of NENs and both NETs and NECs (of small and large cell
types) have been reported. The terminology used over the last
years to define NENs of the larynx has been matter of debate
[29]. In the WHO classification published in 2005, in analogy
with NENs of the lung, they were subdivided into typical car-
cinoid, atypical carcinoid, and neuroendocrine carcinoma
(small and large cell subtype) [30]. Unfortunately, the last edi-
tion of the WHO classification of tumors of the head and neck
published in 2017 [31] changed this terminology resulting in a
problematic and rather confusing scheme, as it misses several
entities and is not in line with the terminology used for thoracic
or digestive NENs. In this context, the most relevant issue
regards the use of the term neuroendocrine carcinoma as a
synonym for NEN, under the heading of which both morpho-
logically well- poorly differentiated neoplasms are included
[31]. This leads to a non-realistic framework, in which a
three-tiered grading of so called “neuroendocrine carcinoma”,
including well-differentiated, moderately differentiated and
poorly differentiated neoplasms [31] introduces a continuum
from very indolent to very aggressive neoplasms that is not
supported by biological and genetic evidences [32, 33].
Consequently, the terminology used in the 2017 WHO classi-
fication to define neuroendocrine neoplasms clearly appears not
appropriate and, most important for the clinical impact on the
patient’s management, the use of the term neuroendocrine car-
cinoma to define a NET is dangerous because can be confound-
ing for clinicians, who can be encouraged to use platinum-
based chemotherapy to treat patients who would not benefit
from it and would only experience severe collateral effects.
Table 1 Specific pituitary neuroendocrine tumors (PitNETs) types*, transcription factor and hormone expression
Cell type TS Hormone Tumor type(s)
Corticotroph TPIT, NeuroD1 ACTH, β-endorphin, MSH •DG corticotroph PitNET
•SG corticotroph PitNET
•Crooke cell PitNET
Somatotroph PIT-1 GH •DG somatotroph PitNET
•SG somatotroph PitNET
Mammosomatotroph PIT-1, ERα GH, prolactin •Mammosomatotroph PitNET
•Mixed somatotroph/lactotroph PitNET
Lactotroph PIT-1, ERα Prolactin •SG lactotroph PitNET
•DG lactotroph PitNET
•Acidophil stem cell PitNET
Thyrotroph PIT-1, TEF, GATA2 TSH •Thyrotroph PitNET
Gonadotroph SF-1, ERα, GATA2 FSH, LH •Gonadotroph PitNET
Null cells None None •Null cell PitNET
*: in the current WHO classification [32], the term adenoma is used instead of PitNET; TS: transcription factor; DG: densely granulated; SG: sparsely
granulated; ERα: estrogen receptor α
Fig. 1 Morphology alone is not able to identify pituitary neuroendocrine
tumors (PitNETs) that will behave in an indolent manner (a) or that will
locally recur with signs of aggressiveness (b) or that will give metastatic
dissemination (c), although in this latter case high cellularity and mitoses
(arrow) are more frequently observed
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Thus, we strongly recommend the use of the common classifi-
cation framework for NENs also in this site, with NETs corre-
sponding to typical and atypical carcinoids of the 2005 classi-
fication, and the termNEC reserved for morphologically poorly
differentiated and clinically aggressive neoplasms [20, 29]. In
addition, it is worth to be noted that in the 2017 WHO classi-
fication there is no mention on mixed neoplasms, which, on the
contrary, have been described in the literature and may repre-
sent a diagnostic challenge for pathologists [19].
In the nasal cavity, the WHO classification only includes
NECs [31], although the existence of NETs and mixed
neuroendocrine-nonneuroendocrine neoplasms (MiNENs)
has been well documented [19, 29, 34]. These two entities,
although rare, need to be recognized because they show dis-
tinct prognosis and deserve a specific therapeutic approach.
A dedicated chapter on salivary gland NENs is not includ-
ed in the 2017 WHO classification of head and neck tumors
and they seem to be included in the chapter of poorly differ-
entiated carcinoma, which also includes cases without a neu-
roendocrine differentiation [31]. Although the spectrum of the
salivary gland NENs is almost totally covered by NECs of the
small cell and large cell subtypes, a few cases of NETs have
been reported and need to be considered among the possible
differential diagnoses [29].
The last entity to be considered among NENs of the head
and neck is the so-called middle ear adenoma. Several studies
have demonstrated that this tumor type is composed of both a
glandular (exocrine) and solid (neuroendocrine) component,
making the neuroendocrine tumor of the middle ear a mixed
neoplasm (Fig. 2), for which the term MiNENs may be more
appropriate [29].
In line with the recent classification framework supported
by the WHO/IARC [20] the terminology used to define head
and neck NEN needs to be revised and in Table 3 a classifi-
cation scheme is proposed.
4 Lung
NENs of the lung are currently classified in four main catego-
ries, including typical carcinoid (TC), atypical carcinoid (AC),
large cell neuroendocrine carcinoma (LCNEC) and small cell
lung carcinoma (SmCLC) [11]. This classification is meant to
be applied on surgical samples, and its mainstays are repre-
sented by morphological parameters: mitotic index, the pres-
ence of necrosis, and cell size, whereas Ki67 proliferation
index is not included in the assessment for classification pur-
poses. Although this terminology is not in line with the al-
ready mentioned common classification framework proposed
by WHO/IARC [20], a substantial overlapping exists. In fact,
TC and AC are considered well differentiated NENs (i.e.,
NETs), whereas LCNEC and SmCLC are regarded as poorly
differentiated NENs (i.e., NECs). Besides these semantic is-
sues, the practicing pathologist has experienced cases in
which the clear-cut separation between, for example, TC and
AC, or AC and LCNEC is not affordably allowed using the
classical morphological parameters and additional workup is
needed to reach a clinically meaningful diagnosis. In fact,
Ki67 proliferation index has proven to be a useful parameter,
at least in two different practical settings. First, on small biop-
sies with crash artifacts impairing the morphological evalua-
tion, Ki67 may have paramount diagnostic value in
distinguishing a NET (carcinoid) from a NEC (LCNEC or
SmCLC) [35–39]. Second, Ki67 proliferation index has been
shown to be a relevant prognostic factor in lung NETs
(carcinoids) and its evaluation should be added to the patho-
logical report, even if no agreement has been reached, until
now, neither on the cut-off levels, nor on the possible integra-
tion with morphological parameters in a grading system sim-
ilar to that of digestive NENs [40]. In addition, and important-
ly, NET (carcinoids) with high Ki67 proliferation index (be-
tween 10% and 20%) have been reported to have peculiar
morphological and clinical features, that resemble those of
digestive NET G3, and may represent a distinct type of ag-
gressive well differentiated pulmonary NEN [41, 42].
The “molecular revolution” of the last decade has involved
pulmonary NENs, as well. Based on the systematic review of
compelling molecular evidences reported in literature, it has
recently been proposed a molecular classification, which rec-
ognizes three different types of lung NENs, showing distinct
molecular signatures and clinical behavior [43, 44]. In detail,
they listed: 1) primary high grade NENs, which are the most
frequent pulmonary NENs (70–75%), are diagnosed on small
biopsies of heavy smokers, arise de novowith no recognizable
precursor lesions, show classic SmCLC or LCNEC morphol-
ogy, have low intra- and inter-tumor genetic heterogeneity
with consistent inactivation of TP53 and RB1, a high mutation
burden, an extremely high Ki67 index, and a very aggressive
clinical behavior, with no role for radical surgery; 2) second-
ary high grade NENs, which represent 20% to 25% of pulmo-
nary NENs, arise in heavy smoker men, have variable mor-
phology (AC, LCNEC, SmCLC), may show the presence of
precursor lesions (neuroendocrine cell hyperplasia/
DIPNECH, neuroepithelial bodies, carcinoids, non-small cell
Table 2 Prognostic classification of pituitary neuroendocrine tumors
Modified from Trouillas et al. 2013 [24]
Grade 1a: non-invasive PitNET
Grade 1b: non-invasive and proliferative PitNET
Grade 2a: invasive PitNET
Grade 2b: invasive and proliferative PitNET
Grade 3: metastatic PitNET (pituitary carcinoma)
Invasion is defined as histological and/or radiological (MRI) signs of
cavernous or sphenoid sinus invasion; Proliferation is considered on the
presence of at least one of two criteria: Ki67 > 3% or mitoses >2/10HPF
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lung carcinoma), have high intra- and inter-tumor genetic het-
erogeneity with involvement of a variety of different pathways
(inactivation of TP53, RB1, and NOTCH, KRAS/LKB1/MEN1
mutation, MYC, TERT, SDHA, RICTOR amplification and
epithelial-mesenchymal transition), suggesting a multistep
pathogenesis, present a heterogeneous Ki67 index, and be-
have less aggressively than the previous type, being diagnosed
mainly on surgical specimen after oncologically radical inter-
vention; 3) indolent low grade NENs, which are the rarest type
(5% of lung NENs), are diagnosed in non-smoker women,
have well differentiated morphology (TC or AC), are often
accompanied by precursor lesions (DIPNECH), may arise in
MEN1 or other familial syndromes, show low mutation bur-
den with involvement of chromatin remodeling genes, have an
evenly low Ki67 index (10% or less), behave indolently and
are successfully treated with surgery. In addition, a growing
burden of evidence has been accumulating in support of
the hypothesis that at least a subset of high grade NENs
(NECs) in this site may arise from the progression of
pre-existent NETs (carcinoids). In a recently published
integrative analyses on 257 lung neuroendocrine neo-
plasms, it was possible to stratify atypical carcinoids
into two prognostic groups with significantly different
10-year overall survival. Interestingly, a third group of
neoplasms with carcinoid-like morphology but molecular
profile closer to that of large cell NEC, defined supra-
carcinoid, suggests a molecular link between carcinoids
and large cell NECs also suggesting the possibility that
a subset of large cell NEC may derive from pre-existing
carcinoids [45].
The combination of morphological, proliferation and mo-
lecular parameters has leaded to the proposal of a comprehen-
sive classification of lung NENs, which follows the common
classification framework for NENs and has important clinical
and therapeutic correlates [46].
5 Breast
The issue of neuroendocrine differentiation in breast neo-
plasms has been a matter of debate since its first description
in 1963 [47]. Indeed, although neuroendocrine phenotype has
been demonstrated in a number of breast tumors using both
immunohistochemical and ultrastructural methods [48–50],
several morphological and genetic considerations prevent the
full inclusion of so-called breast NENs in the common classi-
fication framework of NENs [51]. First, as the current classi-
fication of NENs is primarily based on morphological criteria
that allow the distinction between NETs and NECs, a careful
revision of the so-called breast NETs, as they are defined in
the lastWHO classification of breast tumors [52], shows that a
definite and recognizable morphology is not identified, and
the diagnosis, in practice, relies on immunostains for
synaptophysin and chromogranin A, which are not enough
Table 3 Classification of epithelial head and neck neuroendocrine neoplasms
2005 WHO classification [30] Current (2017) WHO classification [31] Proposed new WHO classification [20]
Typical carcinoid Well-differentiated neuroendocrine carcinoma, grade I NET G1
Atypical carcinoid Moderately differentiated neuroendocrine carcinoma, grade II NET G2
Small-cell NEC and large cell NEC Poorly differentiated neuroendocrine carcinoma, grade III NEC (small and large cell types)
Combined small cell NEC Neuroendocrine carcinoma with non small cell component
(squamous cell carcinoma, adenocarcinoma, etc.)
MiNEN
Fig. 2 The so-called middle ear adenoma should be considered as a mixed neuroendocrine/nonneuroendocrine neoplasm, since it is composed of both a
glandular (exocrine) and a solid (neuroendocrine) component (a), the latter positive for neuroendocrine markers including chromogranin (b)
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to define a NEN [51]. Second, the genetic and expression
profiles of so-called breast NETs is, in fact, overlapping with
that of luminal A breast carcinomas and shares no similarities
with those described for well differentiated NENs of other
sites [53]. Third, the grading system for these neoplasms relies
on the Elston-Ellis criteria and not on the proliferation rates as
in NETs of other anatomical sites [52]. Fourth, which derives
from the previous points, treatment strategies for the so-called
breast NETs do not take in account the presence of neuroen-
docrine differentiation but follow standard protocols for the
carcinomas of the breast of special and no special types [54].
Fifth, and last, there is no significant difference in the outcome
of patients with so-called breast NETs, when compared to
patients with non-neuroendocrine breast carcinomas of the
same grade, stage and molecular profile [52]. Indeed, the ther-
apeutic choices for so-called breast NET rely on predictive
factors traditionally used for non-neuroendocrine breast can-
cer (hormone receptor expression, HER2 hyperexpression and
amplification, and proliferative index) and targeted therapies
for NETs of other sites (somatostatin analogues, mTOR inhib-
itors) have not proved to be effective on Br-NETs [55].
Indeed, although the expression of somatostatin receptors
(SSRs) has been demonstrated in a subgroup of mammary
NETs [56], several studies have demonstrated that SSRs, are
also frequently expressed in breast carcinomas of luminal A
type, removing any specificity of somatostatin analogues in
the management of breast NET [57, 58].
A separate discussion is needed for breast NECs, which,
albeit rare, represent a well-defined entity, showing morpho-
logical and clinical analogies with pulmonary and extra-
pulmonary NECs. In these neoplasms, molecular studies have
demonstrated the presence, in early pathogenetic steps, of al-
terations overlapping those of the non-endocrine breast carci-
noma, similarly to what happens in other sites [59]. Indeed,
these findings are paralleled by the morphological observation
that, in many of these cases, the NEC component is associated
with an in situ or invasive non-endocrine breast carcinoma
[60]. For these reasons, breast NECs may be entitled to be
included in the NENs category [51].
6 Digestive system
The classification of digestive NENs has undergone a signif-
icant evolution over the last 20 years, reflecting the increasing
knowledge on pathogenesis and molecular background of this
heterogeneous group of neoplasms. The last WHO classifica-
tion published in 2019 recapitulates these changes and inte-
grates the most recent clinico-pathologic and molecular find-
ings [17]. It is worth noting that, due to its easy application,
good reproducibility, and great clinical significance, the clas-
sification approach for digestive NENs has been employed as
the model for the common classification framework for NENs
originating in different organs [20]. The basis of the classifi-
cation includes the integration of both morphological (histo-
logical differentiation) and proliferative (grade) features and
identifies three main groups (Table 4 and Fig. 3): well differ-
entiated neuroendocrine tumor (NET), poorly differentiated
neu ro endoc r i n e c a r c i noma (NEC) , and m ixed
neuroendocrine/non-neuroendocrine neoplasm (MiNEN).
The distinction between NET and NEC relies on morphology
and includes specific cellular and architectural criteria [2].
NETs are then graded based on the proliferation index (mitotic
count and Ki67-related proliferation index) and are divided in
three groups (NET G1, NET G2, and NET G3), while NECs
are by definition high grade neoplasms, and the specification
G3 has been removed to avoid confusion with NET G3
(Table 4). This approach has proven to be of great help for
the prognostic stratification of patients and it is particularly
useful for the distinction, among the group of G3 neoplasms
(Ki67 > 20%), between NET G3 and NEC, two entities show-
ing distinct molecular background, clinical outcome, and ther-
apeutic approach. This classification, based on the combina-
tion of both morphology and proliferation, appears as an im-
portant evolution of the WHO classification published in
2010, in which the distinction of NETs from NECs was main-
ly based on the proliferative index [10].
In the current classification scheme, the identification of
NEC is rather easy by combining morphology and prolifera-
tion, and its clinical and prognostic features seem to be similar,
independently of the site of origin. Conversely, NETs show
peculiar site-specific characteristics to be kept in mind and, for
a better prognostic classification of tumors, the WHO classi-
fication needs to be integrated with other parameters, depend-
ing on the anatomical site. In this context, the prognostic role
of Ki67 proliferative index deserves a discussion. Although
the Ki67 proliferative index is a well-known prognostic mark-
er, its prognostic role may vary depending on the tumor type
and the site of origin [61].
In gastric NETs, the best prognostic stratification of pa-
tients is achieved by combining the clinico-pathologic subtype
(type1, type 2, and type 3 gastric NETs), which is per se of
prognostic value, with the Ki67 proliferative index, especially
in patients with type 3 NETs [62].
In duodenal NETs, Ki67 has been demonstrated to be a
predictor of lymph node metastasis and, although, associated
with disease-specific survival at univariate analysis, it failed to
be an independent prognostic factor discriminating survival
between G1 and G2 tumors [63]. For this reason, a
multiparametric approach including tumor size, site (ampulla
versus other duodenal sites), and proliferative activity seems
the most accurate to classify duodenal NETs.
Ileal NETs are peculiar tumors due to their ability to me-
tastasize early to regional lymph nodes and/or the liver despite
a low proliferation index (most tumors are G1). Consequently,
it is conceivable that tumor grading fails to predict the
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metastatic potential of these tumors. However, Ki67 prolifer-
ative index is correlated with prognosis and, interestingly, it
has been demonstrated that the increasing risk for tumor pro-
gression and tumor death for each increasing Ki67 unit was
Fig. 3 Morphology and Ki67
proliferation index of different
NEN types of the digestive
system. Neuroendocrine tumors
(NETs) show a well differentiated
morphology and on the basis of
Ki67 labelling index they can be
divided into G1, G2, and G3 cat-
egory. Neuroendocrine carcino-
mas, both of large cell (LCNEC)
and small cell (SmNEC) subtype,
show poorly differentiated mor-
phology and high Ki67 prolifera-
tive index. H&E: hematoxylin
and eosin
Table 4 WHO classification of
digestive neuroendocrine
neoplasms
Morphological differentiation Mitotic count/2mm2 Ki67 index
NET G1 well-differentiated <2 <3%
NET G2 well-differentiated 2–20 3–20%
NET G3 well-differentiated >20 >20%
NEC poorly differentiated >20 >20%
MiNENs well or poorly differentiated variable variable
NET: neuroendocrine tumor; NEC: neuroendocrine carcinoma: MiNEN: mixed neuroendocrine/non-
neuroendocrine neoplasm
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14% and 18%, respectively [64]. This underlines the biologi-
cal concept that Ki67 should be considered as a continuous
variable and the calculation of the prognostic risk for each
increasing Ki67 unit may be superior to the separation of
tumors using fixed Ki67 categories, which, however, are use-
ful to give a general classification approach.
Among digestive NETs, appendiceal ones are the most
peculiar. Indeed, despite frequent infiltrative growth into the
muscular layer and subserosa, lymph node metastases are rare
and distant metastases are virtually absent [65]. Patients with
these tumors, who often are young, have an excellent outcome
after appendectomy. The Ki67 labeling index, which is gen-
erally low, has recently been demonstrated to predict nodal
metastases together with size >1.5cm and lympho-vascular
invasion. However, the prognostic role of lymph node metas-
tases is still matter of debate since no statistically different
prognosis has been observed between patient with or without
lymph node metastases [65–67]. For this reason, the survival
benefit of right hemicolectomy is still unclear, and its choice
needs to be demanded to multidisciplinary tumor boards in
expert referral centers [66, 68].
About 90% of the rectal NETs are G1 which show better
survival than G2 NETs [69], demonstrating the prognostic role
of tumor grade and consequently of Ki67 proliferative index in
these tumors. However, although tumor grade has been proved
to be a prognostic marker in univariate analysis, it was not
found as an independent factor at the multivariate analysis
[69, 70]. For this reason, it has therefore been suggested that
the best approach for stratifying patients into different prognos-
tic categories seems to be multiparametric considering tumor
grade together with tumor size, lympho-vascular invasion, level
of wall infiltration, and immunophenotype (L-cell versus EC-
cell NET) [69, 70], which have been demonstrated to have a
prognostic role [71]. G1 rectal NETs with a size less than
10 mm, absence of lympho-vascular and muscular layer infil-
tration, and L-cell phenotype require only endoscopic resection,
while larger G2 NETS, especially when of EC-cell type and
deeply infiltrating the rectal wall in the presence of lympho-
vascular invasion, need surgical resection.
Pancreatic NENs (PanNENs) are the tumors where the
prognostic role of Ki67 proliferative index has been most
investigated during the last years [72–75] and it represents
an important prognostic marker together with stage [75].
The current WHO classification is very useful to stratify pa-
tients with PanNENs in different prognostic categories and its
use is strongly recommended. It is worth noting that PanNETs
less than 1 cm with a low proliferation index have been con-
sidered for a long time as benign tumors and, for this reason,
the term pancreatic microadenoma has been proposed.
However, as all other neuroendocrine tumors of the
body, small and low proliferative PanNETs should be
also considered malignant because they can give lymph
node metastases [76].
In addition to NET and NEC, the WHO classification in-
cludes mixed neuroendocrine/ non-neuroendocrine neo-
plasms (MiNENs). The introduction of the term MiNEN, that
we proposed for the first time in 2016 [19], represents an
evolution in the definition of mixed neoplasms. Indeed, the
term MANEC (mixed adenoneuroendocrine carcinoma) in-
cluded in the previous WHO classification [10] did not con-
vey the real spectrum of digestive mixed neoplasms creating
confusion among pathologists and clinician [18]. The advan-
tage of the term MiNEN resides in the fact that all different
entities resulting from the different combinations of various
neoplastic components can be included under this term, which
represents an umbrella covering all different entities.
Consequently, MiNEN should be regarded as a conceptual
category, rather than a specific diagnosis. Indeed, in the pa-
thology report, a diagnosis of MiNEN needs to be better spec-
ified including the correct identification and categorization of
each component [18]. Despite this improvement, a main issue
remains unsolved. By definition, the two components of a
MiNEN should represent at least 30% of the tumor burden,
but this cut-off was arbitrarily chosen presumably to assure
that each component was quantitatively enough to influence
the natural history of the disease and patient’s outcome.
However, no systematic study has been performed, to date,
to confirm the biological validity of this cut-off. The 30% cut-
off seems a dangerous criterion, especially when a minor tu-
mor component (<30%) is represented by a high grade NEC,
which can drive patient’s prognosis independently on its per-
centage. Since in the last WHO classifications to define a
MiNEN the two components are to be “morphologically rec-
ognizable” based on well-established criteria, the maintenance
of the 30% cut off is probably not useful and/or essential. For
this reason, further studies may help to solve this issue.
7 Urogenital system
Neuroendocrine neoplasms (NENs) of the genitourinary tract
are rare, but it is important to be aware of their existence as the
correct diagnosis drives their treatment and prognosis. NENs
have been described in the kidney, urinary bladder, prostate,
testes, uterine cervix, uterine corpus, and ovaries. In all these
organs, except for ovaries and testes, in which NETs are more
frequent, the commonest NEN type is NEC. In the kidney and
in the bladder, non-epithelial NENs (i.e. paragangliomas)
have been described as well. The current classifications of
tumors of the urinary tract and genital organs [77, 78] are
partially in line with the common classification framework
proposed by WHO/IARC [20]. Indeed, NENs of the kidney,
of the urinary bladder and of the uterus are subdivided in
NETs and NECs (with site-related variations), whereas in
the prostate and in the gonads the nomenclature is still con-
fusing and should be revised to adhere to the new criteria [77,
Rev Endocr Metab Disord
78]. In addition, the current classifications do not adequately
recognize that most of poorly differentiated NENs of genito-
urinary tract are, in fact, combined with non-neuroendocrine
components, and the category of MiNEN should be included
in the classification scheme. Here, we will focus on bladder
and prostatic NENs, which represent the main hot topic in the
urogenital region, both because of their frequency and because
of issue related to the nomenclature.
In the urinary bladder most NEN are small cell NECs,
while the large cell subtype is exceedingly rare. Urinary blad-
der NECs are frequently associated with other carcinomatous
components (urothelial and squamous carcinomas and adeno-
carcinoma), constituting bladder MiNENs. Since the poorly
differentiated neuroendocrine component seems to drive the
prognosis in MiNENs, its proper recognition is important for
patients’ management. Immunohistochemical stains for
synaptophysin and chromogranin A help to confirm the neu-
roendocrine differentiation of neoplastic cells, but additional
markers can be used in discriminating and quantifying neuro-
endocrine versus non-neuroendocrine components. It has
been demonstrated that NECs of the urinary bladder are con-
sistently p16-positive, CK20-negative, GATA3-negative, and
p63-negative, whereas high grade urothelial carcinomas show
an opposite profile (p16-, p63+, GATA3+, and CK20+) [79,
80].
In the prostate, the presence of neuroendocrine differentia-
tion, in the sense of general neuroendocrine markers expres-
sion, is relatively frequent and a significant subset of prostatic
adenocarcinomas show immunoreactivity for synaptophysin,
despite the absence of a true neuroendocrine morphology.
Although these cases are listed by the last WHO classification
as belonging to neuroendocrine neoplasms [77], they are not
entitled to be part of the NENs category, as it is currently
defined. Another entity that is included among prostatic neu-
roendocrine neoplasms is the so-called adenocarcinoma with
Paneth cell-like neuroendocrine differentiation, which is de-
fined as a prostatic adenocarcinomawith morphologically rec-
ognizable well-differentiated neuroendocrine cells showing
cytoplasm stippled with brightly eosinophilic granules. The
designation “Paneth cell-like” is a misnomer, as these granules
do not contain lysozyme, as Paneth cells do, but are rather
functionally and morphologically similar to neuroendocrine
cells interspersed in the intestinal mucosa. Therefore, we pre-
fer the designation of adenocarcinomawith well differentiated
neuroendocrine cells for this entity and we consider that,
when neuroendocrine cells are clustered in organoid structures
that represent a significant proportion of the tumor mass, it
should be regarded to as a MiNEN [81]. In this case, the
presence of solid architecture in the neuroendocrine compo-
nent should not be graded as Gleason pattern 5 [82]. Real
NENs of the prostate are mainly represented by NECs.
Prostatic NECs are uncommon neoplasms that may present
in pure neuroendocrine form or as MiNENs, in association
with prostatic adenocarcinoma. About half of cases occur in
patients with a previous diagnosis of prostatic adenocarcino-
ma treated with androgen deprivation therapy, which has be-
come castration-resistant. However, prostatic NEC may also
occur de novo [81]. NETs are exceedingly rare in the prostate,
and their existence itself is questioned. They may be diag-
nosed only when all the following criteria are satisfied: 1-
presence of well differentiated neuroendocrine morphology;
2- absence of adenocarcinomatous component; 3- immuno-
histochemical expression of general neuroendocrine markers;
4- negativity of immunostainings for AR and PSA; 5- exclu-
sion of prostatic metastasis or infiltration from a primary NET
of another site. The main diagnostic problem on small biop-
sies is to distinguish prostatic NET from NEC, which has
completely different prognostic implications [81]. The spec-
trum of prostatic neoplasms with neuroendocrine differentia-
tion has been recently expanded by an entity called prostatic
carcinoma with amphicrine features, an aggressive variant of
prostatic carcinoma in which the totality of neoplastic cells
present both a neuroendocrine and an exocrine phenotype
[83]. However, it is important to recall that amphicrine neo-
plasms do not belong to the category of NENs, as they are
currently defined [18].
8 NENs of unknown primary origin
Virtually all NENs have metastatic potential and up to 20% of
the cases present as metastasis from an occult primary
[84–86]. The identification of the primary site is an important
step towards the correct management of the patient, particu-
larly when dealing with a NET since the therapeutic approach
may vary depending on the site and cell type. In contrast,
NECs, independent of the primary site, are currently treated
with platinum-based regimens [87]. In this context, the role of
the pathologist may be limited to the distinction between a
visceral NEC and aMerkel cell carcinoma of the skin, because
the latter requires wide local excision, sentinel node biopsy
and, possibly, radiotherapy [88]. In contrast, thorough mor-
phological and immunohistochemical analyses combined
with imaging techniques are expected to give important clues
to the recognition of the site of origin of a metastatic
NET [89].
Among NETs, the tendency to metastasize is highest for
those of pancreatic origin, followed by small intestinal, colon-
ic, pulmonary and gastric neoplasms [87]. Irrespective of the
primary site, the liver represents the most frequent location of
metastatic NENs; lymph nodes, peritoneum, bone and lung
represent further usual secondary sites [86]. However, virtu-
ally any body organ including those that can give rise to pri-
mary NENs may host metastatic NENs, including breast, ova-
ry, thyroid, pancreas and pituitary [89]. Thus, it becomes ev-
ident that the diagnosis of a metastatic NEN gives rise to two
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orders of problems: (i) the identification of the occult primary
site, and (ii) the distinction from a putative primary NEN of
the organ in which the lesion is present. Both challenges are of
crucial importance in the management of patients and the pa-
thologist should be aware of the diagnostic tools to approach
them and of the entities, which enter in the differential diag-
nosis. To address these issues, a coordinated and comprehen-
sive clinical and pathological investigation is required. A di-
agnostic algorithm to identify the primary site of neuroendo-
crine neoplasms of unknown origin by using radiological and
endoscopic methods along with radionuclear markers has
been proposed [87]. From a pathological point of view, the
critical employment of immunohistochemical stains for tran-
scription factors and hormonal products has proved to be ef-
fective in identify the primary site of a metastatic NET, and the
reader is referred to specific papers for detailed dissertation
and diagnostic flowcharts [1]. Importantly, after the primary
site has been identified, a careful grading and site-specific
staging of the NET is crucial. In this context, the application
of the common framework for the nomenclature and classifi-
cation of NENs [20] shows, in our opinion its great value in
guiding the physician hand in the management of these neo-
plasms, as the subdivision in NET, NEC andMiNEN families,
independently of the primary site, provides an important initial
characterization of the disease. Then, for the best treatment,
this has to be obviously placed in the context of the specific
site of origin of the NET.
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